Posted by Amy Clausen on Mon, Oct 05, 2009 @ 10:51 AM
MD Biosciences (MDB), a contract research organization offering
pre-clinical services and products in support of drug discovery for
inflammatory and neurological diseases, relocated its U.S. office from
1000 Westgate Dr, St Paul, MN to 2575 University Ave W, St Paul, MN on
October 3, 2009. The new location equips MD Biosciences with more lab
space, allowing for increased capacity for in vitro services and
product development and manufacturing to increase product offering.
Eddie
Moradian, President of MD Biosciences states, "At MD Biosciences, we
have always promised our clients that we will meet their needs now and
in the future; our expansion ensures that commitment. We doubled our
lab space so that we are able to provide 150 percent more services and
increase product development by 130 percent in the coming year in
comparison with the last.
Our relocation is just one step of
many in the endeavor to continue to offer the highest quality services
and products in assisting our customers in meeting their objectives.
Future projections include adding more highly specialized scientists to
our team and increasing our focus on our available products and
proprietary reagents."
About MD BiosciencesMD
Biosciences provides products and pre-clinical services, which include
efficacy testing, mode of action platforms, in vitro analysis,
histology and imaging for the Pharmaceutical, Medical Device and Animal
Health & Nutrition Industries. We offer several novel models in the
area of rheumatoid arthritis (RA), Multiple sclerosis, asthma, IBD,
pain, and Parkinson's disease. The in-depth expertise in these disease
models has been applied to designing protocols to assess the efficacy
and required dosage of novel compounds. Contracted studies are designed
and reviewed by MDB’s panel of internationally recognized experts and
performed at one of MDB’s specialized laboratories located in St. Paul,
MN (USA), Glasgow (Scotland) or in Israel . We provide a ready team of
experts to tackle problems and provide solutions. MDB also supplies for
purchase by all laboratories many of the products and proprietary
reagents used in our research, regardless of whether MDB is contracted
as a research organization. This allows our clients to optimize their
own research process by selecting steps to be performed by MDB and
research to be performed in-house.
###
The
information in this press release should be considered accurate only as
of the date of the release. MD Biosciences has no intention of updating
and specifically disclaims any duty to update the information in these
press releases.
Posted by Amy Clausen on Wed, Mar 04, 2009 @ 11:03 AM
Wednesday, March 4, 2009, St. Paul, MN - MD Biosciences, a Preclinical Contract Research Organization (CRO), announces today that it has expanded its preclinical contract research services by launching a line of in vivo models for the study o fmyocardial infarct and vascular disease. These models enable the evaluation of drug treatment for myocardial infarct.
New models include:
- Ligation induced acute cardiac infarction
- Coil-induced acute cardiac infarction
- Balloon-induced cardiac ischemia reperfusion
- Multi-focal myocardial infarct
- Induction of vascular disease
These models offer the flexibility of protocol design for monitoring a variety of parameters such as ECG, invasive blood pressure, SpO2, ETCO2, and PPV. Readouts offered include ECG, Echo, Angiography, cardiac MRI and blood tests for relevant parameters such as CPK. All tests are analyzed by expert cardiologists in collaboration with the Heart Institute, Sheba Medical Center of the Tel Aviv University.
The expansion of these service capabilities, along with the addition of scientific staff, indicates the stability and forward growth of the company. MD Biosciences complete services portfolio offers efficacy testing, mode of action analysis, biomarker and gene expression analysis and histopathology services. In vivo models include Collagen Induced Arthritis (CIA), Antibody Induced Arthritis, OVA-induced Asthma, DSS and TNBS induced IBD, EAE/Multiple Sclerosis, Neuropathic Pain, Nociceptive Pain, Post-operative Pain and Parkinson’s Disease. In vitro cell based services include assays for screening of inflammatory effects, cell signaling pathway screens, enzyme inhibition assays as well as molecular mode of action assays.
eba Medical Center of the Tel Aviv University.
The expansion of these service capabilities, along with the addition of scientific staff, indicates the stability and forward growth of the company. MD Biosciences complete services portfolio offers efficacy testing, mode of action analysis, biomarker and gene expression analysis and histopathology services. In vivo models include Collagen Induced Arthritis (CIA), Antibody Induced Arthritis, OVA-induced Asthma, DSS and TNBS induced IBD, EAE/Multiple Sclerosis, Neuropathic Pain, Nociceptive Pain, Post-operative Pain and Parkinson’s Disease. In vitro cell based services include assays for screening of inflammatory effects, cell signaling pathway screens, enzyme inhibition assays as well as molecular mode of action assays.
About MD Biosciences
MD Biosciences is a Preclinical Contract Research Organization (CRO) providing services and products for biotech/pharmaceutical, medical device and animal health and companies engaged in inflammations & neurology research. With specialized laboratories located in Minnesota, Glasgow, and Israel, our panel of internationally recognized experts provides in-depth expertise and technologies to overcome challenges and provide total solutions to the drug discovery market.
--------
The information in this press release should be considered accurate only as of the date of the release. MDB has no intention of updating and specifically disclaims any duty to update the information in these press releases.
Posted by Amy Clausen on Wed, Sep 10, 2008 @ 11:23 AM
MD Biosciences, a global biotechnology company focused in inflammations and neurology research, is expanding its line of arthritis and pain preclinical services with the addition of the CFA-induced monoarthritic pain model. The model offers advantages over traditional arthritis models in that disease develops in only one joint allowing a comparison to the healthy joint. The quantification of pain associated with arthritis can be useful in elucidating the mechanisms of arthritis as well as evaluating the efficacy of anti-arthritic drug compounds in the discovery phase.
The monoarthritic pain model is a 28-day model with arthritis and subsequent pain present in a single joint. Pain response develops 1 day post-induction. Readouts available are clinical signs and scoring, body weights, mechanical and thermal stimuli, weight bearing, histology and cytokine analysis.
In addition to the monoarthritic pain model, MD Biosciences offers the traditional Adjuvant-induced arthritis model that allows for traditional pain measurements as well as a record of spontaneous pain using the Foot Print of Pain method. Other Arthritis models and research reagents include the Collagen Induced Arthritis (CIA) and Collagen Antibody Induced Arthritis (CAIA), ArthritoMab™ Arthritogenic Antibody Cocktail, Collagen Reagents, Collagen Antibodies and Collagen-related ELISA Kits and Assays.
About MD Biosciences
MD Biosciences provides products and pre-clinical services for companies engaged in inflammations and neurology research. The company is headquartered in Switzerland and has specialized laboratories located in the United States, United Kingdom, and Israel. A panel of scientific experts provides companies’ in-depth expertise and technologies to tackle problems and provide flexible drug discovery solutions, enabling smarter results faster.
###
The information in this press release should be considered accurate only as of the date of the release. MD Biosciences has no intention of updating and specifically disclaims any duty to update the information in these press releases.